St. Jude Medical, Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the Company is working cooperatively with the U.S. Food and Drug Administration (FDA) to resolve current Good Manufacturing…
St. Jude Medical, Inc. disclosed in its latest quarterly report on
Form 10-Q filed with the U.S. Securities and Exchange Commission
that the Company is working cooperatively with the U.S. Food and
Drug Administration (FDA) to resolve Epicor LP Cardiac Ablation
System and the…
St. Jude Medical, Inc. disclosed in its latest quarterly report on
Form 10-Q filed with the U.S. Securities and Exchange Commission
that the company continues to respond to a Civil Investigative
Demand initiated by the U.S. Department of Justice (DOJ).
In March 2010, the…
St. Jude Medical, Inc. disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with the Boston U.S. Attorney investigation.
In December 2008, the U.S. Attorney’s Office in Boston delivered…
Seven individual state court suits concerning Silzone(R)-coated products filed against St. Jude Medical, Inc. were pending as of April 24, 2009, the Company disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission.
Silzone(R)…
Three individual Silzone(R) cases were pending against St. Jude Medical, Inc. in the U.S. federal court as of April 24, 2009, disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission.
Silzone(R) is a…